BioAge Labs
BIOA
65 hedge funds and large institutions have $114M invested in BioAge Labs in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 29 closing their positions.
24% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 29
12% more funds holding
Funds holding: 58 → 65 (+7)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
74% less capital invested
Capital invested by funds: $431M → $114M (-$317M)
1,149.26% less ownership
Funds ownership: 1,204.05% → 54.79% (-1,149%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$22.7M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$17.2M |
| 3 |
BlackRock
New York
|
+$12.3M |
| 4 |
Morgan Stanley
New York
|
+$7.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$20.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.36M |
| 4 |
O
OrbiMed
New York
|
-$8.65M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$6.97M |
BIOA Hedge Fund Activity: Q4 2024 in Review
65 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in BioAge Labs (BIOA) for Q4 2024, worth a combined $114M — down 74% from $431M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new BIOA positions and 29 closed out — a net gain of 7 holders — while 11 added to existing stakes and 11 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $22.7M. The largest seller was AllianceBernstein, exiting entirely with an estimated $20.7M sold.
- 65 institutional investors held BioAge Labs (BIOA) as of Q4 2024, up from 58 in Q3 2024.
- Funds reported $114M of BioAge Labs stock for Q4 2024, down 74% quarter-over-quarter.
- 36 funds opened new BioAge Labs positions in Q4 2024 and 29 closed out, a net change of +7 holders.
- The largest BioAge Labs buyer in Q4 2024 was Tang Capital Management, an estimated $22.7M added.
- The largest BioAge Labs seller in Q4 2024 was AllianceBernstein, an estimated $20.7M sold.
Based on aggregated 13F filings for Q4 2024.